GLP-1 and Exercise

GLP-1 medications cause weight loss that includes both fat and lean mass — approximately 25–40% of weight lost on semaglutide is lean tissue (muscle and bone mass), compared to ~25% with dietary restriction alone.

Resistance training is critical to minimize muscle loss on GLP-1 therapy. Understanding how GLP-1 medications interact with exercise — fueling, timing, intensity, and recovery — helps maximize fat loss while preserving the muscle that drives long-term metabolic health.

The muscle loss seen with GLP-1 medications (25–40% of total weight loss) is significantly greater than the ~25% lean mass loss typical of dietary restriction alone.

This difference likely reflects the profound caloric deficit created by GLP-1-driven appetite suppression — the body has insufficient protein turnover to maintain muscle mass in the absence of anabolic stimulus.

Resistance training (weight training, bodyweight exercises, resistance bands) provides the mechanical stimulus that preserves myofibrillar protein during caloric restriction. Clinical guidelines increasingly recommend combining resistance training 3x/week with adequate protein intake (1.6–2.2 g/kg of target body weight per day) as standard of care for patients on GLP-1 medications to protect muscle mass.

The reduced appetite from GLP-1 medications can create workout fueling challenges — particularly for high-intensity training that requires carbohydrate availability.

Common issues include: feeling insufficiently fueled pre-workout, reduced performance on fasting training sessions, and longer recovery times due to protein underfeeding. Strategies: (1) Schedule a small protein-containing meal 1–2 hours before training.

(2) Prioritize protein targets (aim for 25–40g protein per meal to maximize muscle protein synthesis). (3) For endurance training, consume easily digestible carbohydrates before sessions. (4) Monitor energy levels and reduce training intensity during dose escalation phases when nausea and appetite suppression are strongest.

Yes — semaglutide (Ozempic/Wegovy) causes muscle loss as part of its overall weight loss effect, but this is a common feature of all significant weight loss interventions, not unique to GLP-1 medications.

In STEP trials, approximately 39% of total weight loss on semaglutide 2.4 mg was from lean tissue (muscle + bone), compared to ~25% with diet alone. This proportionally higher lean mass loss with GLP-1 medications vs dietary restriction alone is attributed to the profound appetite suppression reducing protein intake.

Mitigation strategies: adequate protein intake (1.6–2.2 g/kg/day) + resistance training 3x/week + careful monitoring of body composition (not just weight) are essential to preserve muscle while losing fat on GLP-1 therapy.

Yes — exercise is strongly recommended on semaglutide and other GLP-1 medications.

Specifically, resistance training is critically important to prevent the proportionally higher lean mass loss seen with GLP-1 therapy vs diet alone. The SELECT trial demonstrated that semaglutide-treated patients showed improved cardiorespiratory fitness markers at 1 year, suggesting GLP-1 therapy may synergize with aerobic exercise for cardiovascular health.

Practical recommendations: start with moderate intensity during dose escalation (when GI side effects are strongest), progress to 3+ days/week resistance training + 150 /week moderate aerobic exercise.

Some patients experience improved exercise tolerance after initial adjustment period as energy levels stabilize on maintenance dose.

Preserving muscle on GLP-1 medications requires a multi-pronged approach: (1) Protein intake — target 1.6–2.2 g of protein per kg of target (goal) body weight per day.

With GLP-1-reduced appetite, prioritizing protein at every meal is essential. Consider protein shakes if solid food tolerance is limited. (2) Resistance training — 3 sessions/week minimum, progressive overload (gradually increasing weight/reps).

Compound movements (squat, deadlift, press, ) are most efficient. (3) Adequate caloric floor — avoid extreme caloric restriction below 1200 kcal/day for women, 1500 kcal/day for men as this accelerates lean mass loss.

(4) Consider creatine supplementation — the most well-studied supplement for muscle preservation during caloric restriction, with 3–5 g/day shown safe and effective. (5) Monitor with DEXA scan — track lean mass not just weight to ensure composition improves.

Clinical Evidence GLP-1 and Exercise protocols are supported by clinical research — Shotlee helps you track your own data against published benchmarks. Protocol Tracking Log each dose with exact timing and amount.

Consistent records help you and your provider optimize your protocol. Outcome Monitoring Track your key metrics before and during treatment. Objective data leads to better decisions than memory alone. Side Effect Log Record reactions immediately after each dose.

Pattern detection prevents minor issues from becoming serious problems. Progress Trends Shotlee charts your data over weeks and months — see long-term trends that individual data points can hide. Data-Driven Dosing Your logged data tells you what works.

Use Shotlee charts to make evidence-based adjustments to dose and timing.